Improved survival after allogeneic transplantation for acute lymphoblastic leukemia in adults: a Danish population-based study
Research output: Contribution to journal › Journal article › Research › peer-review
We investigated trends of survival in a population-based cohort study of all 181 adults who received HCT for ALL in Denmark between 2000–2019. Patients had a median (min–max) age of 36 (18–74) years at HCT and were followed for a median of eight years. Overall survival (OS) improved over time with an estimated 2-year OS of 49% (CI 27–66%) in year 2000 versus 77% (CI 59–88%) in year 2019. More patients achieved cure over time (OR for cure per year 1.07, CI 1.00–1.15), while the rate of death in non-cured patients remained stable (HR of excess mortality per year 0.99, CI 0.93–1.06). Relapse decreased over time (HR 0.92 per year, CI 0.87–0.98), whereas non-relapse mortality did not change notably (HR 0.98 per year, CI 0.93–1.04). In conclusion, survival after HCT in adults with ALL has improved over the past two decades, primarily due to more patients achieving cure.
Original language | English |
---|---|
Journal | Leukemia and Lymphoma |
Volume | 63 |
Issue number | 2 |
Pages (from-to) | 416-425 |
ISSN | 1042-8194 |
DOIs | |
Publication status | Published - 2022 |
Bibliographical note
Publisher Copyright:
© 2021 Informa UK Limited, trading as Taylor & Francis Group.
- acute lymphoblastic leukemia, ALL, allogeneic hematopoietic stem cell transplantation, Allogeneic transplantation, survival
Research areas
ID: 288208331